Answers are grounded in this paper and cite their sources.
BACKGROUND Hyperbaric oxygen therapy (HBOT) can modulate inflammatory and redox-sensitive pathways, but its effects on endocannabinoid system markers remain unclear. This exploratory biomarker subanalysis of a randomized controlled parent trial evaluated whether repeated HBOT was associated with changes in serum anandamide (AEA) and lipopolysaccharide (LPS) as primary outcomes. Cannabinoid receptor type 2 (CB2R), fatty acid amide hydrolase (FAAH), and the baseline AEA-LPS association were assessed secondarily or exploratorily. MATERIAL AND METHODS The resource-limited, post-randomization sample included 17 healthy, physically active men: 9 from a pre-existing morning scheduling subgroup of the frequent-treatment HBOT arm and 8 controls selected before biomarker assays to improve baseline body mass index (BMI) comparability. HBOT consisted of 10 sessions performed 6 times weekly. Each session involved 60 minutes of 100% oxygen at 2.5 atmospheres absolute, delivered as three 20-min oxygen-breathing periods separated by two 5-minute air breaks. Fasting serum was collected before and after the protocol, and biomarkers were measured using enzyme-linked immunosorbent assays. RESULTS No significant between-group differences in change scores were found for AEA (p = 0.597), CB2R (p=1.000), FAAH (p=0.885), or LPS (p=0.885). No significant within-group changes occurred in the HBOT group. Baseline AEA was positively associated with baseline LPS (Spearman's rho=0.505, p=0.039). CONCLUSIONS Receiving 10 HBOT sessions were not associated with significant changes in the measured circulating biomarkers. These exploratory findings do not exclude smaller effects, and the baseline AEA-LPS association requires confirmation in adequately powered studies.
No takes yet. Share an insight, caveat, or question.
Wiącek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: